A combination of high-dose vitamin D, omega-3 fatty acids and a simple home strength exercise program (SHEP) can cumulatively reduce the risk of cancer in healthy adults over the age of 70 by 61 percent, the international DO-HEALTH study led by the University of Zurich has shown. It is the first study to test the combined benefit of three affordable public health interventions for the prevention of invasive cancers. The results could influence the future of cancer prevention in older adults.
Cancer is considered a major age-related disease in Europe and the US. It is the second leading cause of mortality in older adults and the chances of getting most cancers increases with age. Apart from preventative recommendations such as not smoking and sun protection, public health efforts that focus on cancer prevention are limited, according to Heike Bischoff-Ferrari, professor of geriatric medicine and aging research at the University of Zurich and the UniversityHospital Zurich: “Preventive efforts in middle-aged and older adults today are largely limited to screening and vaccination efforts.”
Vitamin D, omega-3 and exercise
Previous studies have shown that vitamin D inhibits the growth of cancer cells. Similarly, omega-3 may inhibit the transformation of normal cells into cancer cells, and exercise has been shown to improve immune function and decrease inflammation, which may help in the prevention of cancer. However, there was a lack of robust clinical studies proving the effectiveness of these three simple interventions, alone or combined.
Bischoff-Ferrari and her colleagues wanted to fill these knowledge gaps by testing the effect of daily high-dose vitamin D3 (one form of vitamin D supplements), daily supplemental omega-3s, and a simple home exercise program, alone and in combination, on the risk of invasive cancer among adults aged 70 or older. “Novel cancer treatments aim to block multiple pathways for cancer development by combining several agents. We translated this concept into cancer prevention,” explained Bischoff-Ferrari.
A combination of simple treatments
To do so, the researchers conducted the DO-HEALTH trial: A three-year trial in five European countries (Switzerland, France, Germany, Austria, and Portugal) with 2,157 participants.
The participants were randomized into eight different groups to test the individual and combined benefit of the interventions: Group one received 2,000 IU per day of vitamin D3 (equivalent to > 200% the amount of current recommendations for older adults, which is 800 IU per day), 1g per day of omega-3s, and three times per week SHEP; group two received vitamin D3 and omega-3s; group three received vitamin D3 and SHEP; group four received omega-3s and SHEP; group five received only vitamin D3; group six received only omega-3s; group seven only had SHEP; and the last group received a placebo.
Participants received check-up phone calls every three months and had standardized examinations of health and function in the trial centers at baseline, year one, year two, and year three.
Preventing invasive cancer
The results show that all three treatments (vitamin D3, omega-3s, and SHEP) had cumulative benefits on the risk of invasive cancers. Each of the treatments had a small individual benefit but when all three treatments were combined, the benefits became statistically significant, and the researchers saw an overall reduction in cancer risk by 61%.
“This is the first randomized controlled trial to show that the combination of daily vitamin D3, supplemental marine omega-3s, and a simple home exercise program may be effective in the prevention of invasive cancer among generally healthy and active adults aged 70 and older,” Bischoff-Ferrari commented.
The results may impact the future of invasive cancer prevention in older adults. Bischoff-Ferrari concluded: “Our results, although based on multiple comparisons and requiring replication, may prove to be beneficial for reducing the burden of cancer. Future studies should verify the benefit of combined treatments in the prevention of cancer, also extending to longer follow-ups beyond the three-year duration assessed in this trial.”